SAT0456 The incidence of cardiovascular events in italian patients with systemic lupus erythematosus is lower than in north european and american cohorts: implication of disease–associated and traditional risk factors as emerged by a 16-year retrospective girrcs study (original) (raw)

2018, Saturday, 16 JUNE 2018

European-American Consensus Group (EACG) criteria. Statistical analysis was performed using the SPSS vs.20 package Results: 348 patients (331 women), mean age at diagnosis 56.12±14.19 years (range 22-92), with possible SS were analysed. All patients met the European criteria for SS diagnosis, and 242 the EACG criteria. AAN were positive in 345 (99.4%) patients, RF in 169 (48.4%), anti-Ro60/SSA in188 (54%), and anti-La/ SSB in 11 (32%). Anti-Ro52 abs. were positive in 173 (49.7%) patients: 162 women, 11 men. Of these patients, 154 (89%) also had anti-Ro60/SSA positive abs., 103 (59.5%) anti-La/SSB abs., and 117 (67.6%) positive RF. Anaemia, leukopenia, lymphocytopenia and hypergammaglobulinemia, were significantly more frequent in patients with anti-Ro52 positive abs. The presence of anti-Ro52 abs. was significantly related to the development of lung fibrosis (OR 2.42, 95% CI 1.23-4.75, p=0.007), peripheral neuropathy (OR 2.53, 95% CI 1.1-5.95, p=0.022), arthritis (OR 1.95, 95% CI 1.2-3.35, p=0.016) and parotitis (OR 3.04, 95% CI 1.75-5.3, p<0.001). A total of 160/173 (92.5%) patients with anti-Ro positive abs. met the EACG criteria. When we analysed the 13 patients with anti-Ro52 positive abs., which did not meet the AECG criteria, these patients presented severe salivary gland scintigraphic involvement, positive ocular test for dry eyes, more hypergammaglobulinemia (OR 6.67, 95% CI 1.95-22.8, p=0.003), more peripheral neuropathy (OR 13.8, 95% CI 2.1-92.7, p=0.0012), more lung fibrosis (OR 13.95, 95% CI 2.1-93.7, p=0.012), and more risk of lymphoma development (OR 16.72, 95% CI 1.4-199.8, p=0.039), than patients with suspected SS who did not met the AECG criteria and who had negative anti-Ro52 abs. Conclusions: in our series most patients with anti-Ro52 positive antibodies had also anti-Ro60/SSA positive antibodies and met the AECG criteria. However, there were 13 patients with positive anti-Ro52 abs., which did not meet the AECG criteria. These patients showed similar characteristics to those with positive anti-Ro52 abs. and AECG criteria, and had more risk to develop peripheral neuropathy, lung fibrosis and lymphoma. Our results support that anti-Ro52 antibodies should be included in the diagnostic criteria for SS.